Estrogen Receptor Β Attenuates Renal Fibrosis by Suppressing the Transcriptional Activity of Smad3
Rong Cao,Wen Su,Jingyi Sheng,Yanlin Guo,Jie Su,Cong Zhang,Honglian Wang,Yizhe Tang,Lei Chen,Rongfang Qiao,Xiaocong Chen,Xiaoru Huang,Yunfeng Zhou,Lizhen Zhu,Zirui Bai,Xiaoyan Zhang,Jan-Ake Gustafsson,Qijun Wan,Hui-yao Lan,Youfei Guan
DOI: https://doi.org/10.1016/j.bbadis.2023.166755
2023-01-01
Abstract:Renal fibrosis (RF) is a common pathway leading to chronic kidney disease (CKD), which lacks effective treatment. While estrogen receptor beta (ERβ) is known to be present in the kidney, its role in RF remains unclear. The present study aimed to investigate the role and underlying mechanism of ERβ during RF progression in patients and animal models with CKD. We found that ERβ was highly expressed in the proximal tubular epithelial cells (PTECs) in healthy kidneys but its expression was largely lost in patients with immunoglobin A nephropathy (IgAN) and in mice with unilateral ureter obstruction (UUO) and subtotal nephrectomy (5/6Nx). ERβ deficiency markedly exacerbated, whereas ERβ activation by WAY200070 and DPN attenuated RF in both UUO and 5/6Nx mouse models, suggesting a protective role of ERβ in RF. In addition, ERβ activation inhibited TGF-β1/Smad3 signaling, while loss of renal ERβ was associated with overactivation of the TGF-β1/Smad3 pathway. Furthermore, deletion or pharmacological inhibition of Smad3 prevented the loss of ERβ and RF. Mechanistically, activation of ERβ competitively inhibited the association of Smad3 with the Smad-binding element, thereby downregulating the transcription of the fibrosis-related genes without altering Smad3 phosphorylation in vivo and in vitro. In conclusion, ERβ exerts a renoprotective role in CKD by blocking the Smad3 signaling pathway. Thus, ERβ may represent as a promising therapeutic agent for RF.